[1] Call GK, Fleming MC, Sealfon S, Levine H, Kistler JP, Fisher CM. Reversible cerebral segmental vasoconstriction[J]. Stroke, 1988, 19:1159-1170.
[2] Ducros A. Reversible cerebral vasoconstriction syndrome[J]. Lancet Neurol, 2012, 11:906-917.
[3] Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 1:epidemiology, pathogenesis, and clinical course[J]. AJNR Am J Neuroradiol, 2015, 36:1392-1399.
[4] Ducros A, Fiedler U, Porcher R, Boukobza M, Stapf C, Bousser MG. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome:frequency, features, and risk factors[J]. Stroke, 2010, 41:2505-2511.
[5] Ducros A. Reversible cerebral vasoconstriction syndrome[J]. Presse Med, 2010, 39:312-322.
[6] Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review:reversible cerebral vasoconstriction syndromes[J]. Ann Intern Med, 2007, 146:34-44.
[7] Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients[J]. Brain, 2007, 130(Pt 12):3091-3101.
[8] Jhang KM, Lin CH, Lee KW, Chen YY. Bath-related thunderclap headache associated with subarachnoid and intracerebral hemorrhage[J]. Acta Neurol Taiwan, 2013, 22:127-132.
[9] Takemaru M, Takeshima S, Hara N, Himeno T, Shiga Y, Takeshita J, Takamatsu K, Nomura E, Shimoe Y, Kuriyama M. Reversible cerebral vasoconstriction syndrome:a clinical study of 11 cases[J]. Rinsho Shinkeigaku, 2018, 58:377-384.
[10] Topcuoglu MA, Singhal AB. Hemorrhagic reversible cerebral vasoconstriction syndrome:features and mechanisms[J]. Stroke, 2016, 47:1742-1747.
[11] Squier W, Mack J, Green A, Aziz T. The pathophysiology of brain swelling associated with subdural hemorrhage:the role of the trigeminovascular system[J]. Childs Nerv Syst, 2012, 28:2005-2015.
[12] Troger J, Kieselbach G, Teuchner B, Kralinger M, Nguyen QA, Haas G, Yayan I, Göttinger W, Schmid E. Peptidergic nerves in the eye, their source and potential pathophysiological relevance[J]. Brain Res Rev, 2007, 53:39-62.
[13] Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury[J]. J Cereb Blood Flow Metab, 2009, 29:1388-1398.
[14] Ducros A. Reversible cerebral vasoconstriction syndrome[J]. Rev Neurol (Paris), 2010, 166:365-376.
[15] Elstner M, Linn J, Müller-Schunk S, Straube A. Reversible cerebral vasoconstriction syndrome:a complicated clinical course treated with intra-arterial application of nimodipine[J]. Cephalalgia, 2009, 29:677-682.
[16] Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome[J]. Neurology, 2017, 88:228-236.
[17] Hajj-Ali RA, Furlan A, Abou-Chebel A, Calabrese LH. Benign angiopathy of the central nervous system:cohort of 16 patients with clinical course and long-term followup[J]. Arthritis Rheum, 2002, 47:662-669.